Johnson & Johnson (FRA:JNJ)
161.74
+0.38 (0.24%)
At close: Nov 10, 2025
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B USD in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
4.99
Revenue / Employee
$667.26K
Employees
138,100
Market Cap
392.93B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
Johnson & Johnson News
- 1 day ago - See Which Of The Latest 13F Filers Holds JNJ - Nasdaq
- 1 day ago - Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating - Seeking Alpha
- 4 days ago - FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression - Benzinga
- 4 days ago - FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression - Benzinga
- 4 days ago - JNJ Gains FDA Nod for New DARZALEX Faspro Indication - GuruFocus
- 4 days ago - Johnson & Johnson: Dividends Don't Lie - Seeking Alpha
- 4 days ago - Johnson & Johnson (JNJ) Gains FDA Approval for DARZALEX FASPRO in HR-SMM - GuruFocus
- 5 days ago - DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma - PRNewsWire